SCHEMBL2452890

SCHEMBL2452890

CN(c1ccc(F)c(NC(=O)Nc2ccc(C(F)(F)F)cc2Cl)c1)c1ccc2nc(NC(=O)C3CC3)sc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.58
BRAF P15056 10/20 0.58
IKBKB O14920 1/20 0.58
RAF1 P04049 1/20 0.58
ERBB2 P04626 1/20 0.58
CDK1 P06493 1/20 0.58
PDGFRB P09619 1/20 0.58
KIT P10721 1/20 0.58
SRC P12931 1/20 0.58
PDGFRA P16234 1/20 0.58
FGFR3 P22607 1/20 0.58
MAP2K1 Q02750 1/20 0.58
TEK Q02763 1/20 0.58
MAPK14 Q16539 1/20 0.58
AURKB Q96GD4 1/20 0.58
RIPK3 Q9Y572 4/20 0.42
RIPK1 Q13546 3/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2455663 0.94 KDR (0.58) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL12305934 0.92 KDR (0.56) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2458469 0.90 KDR (0.57) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2457095 0.87 KDR (0.57) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2455652 0.85 KDR (0.58) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2454836 0.84 BRAF (0.61) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2458441 0.83 KDR (0.59) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2450792 0.78 KDR (0.54) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL2453176 0.78 BRAF (0.55) KDRBRAFIKBKBRAF1ERBB2
SCHEMBL12305930 0.77 MAPK14 (0.54) KDRBRAFIKBKBRAF1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2399921-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-12 EP disclosed
US-8697874-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-15 US disclosed
EP-2399921-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-12-28 EP disclosed
EP-2399921-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-12-28 EP disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
WO-2010064611-A1 HETEROCYCLIC COMPOUND AND USE THEREOF 武田薬品工業株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NR3C2, RAF1 KDR 432/4885BRAF 1/4885IKBKB 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.